Diabetes Research and Clinical Practice
Volume 72, Issue 1 , Pages 61-67 , April 2006

Enhancement of serum lipoprotein lipase mass levels by intensive insulin therapy

Received 19 May 2005 ,Revised 11 July 2005 ,Accepted 13 September 2005.

References 

  1. Nilsson-Ehle PA, Garfinkel AS, Schotz MC. Lipolytic enzymes and plasma lipoprotein metabolism. Annu. Rev. Biochem. 1980;49:667–693
  2. Louis CS, Henry JP. Lipoprotein Lipase, Lipases. Amsterdam: Elsevier; 1984;pp. 263–305
  3. Braun JEA, Severson DL. Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem. J. 1992;287:337–347
  4. Sexena U, Klein MG, Goldberg IJ. Transport of lipoprotein lipase across endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1991;88:2254–2258
  5. Sexena U, Wit LAD, Goldberg IJ. Release of endothelial cell lipoprotein lipase by plasma lipoproteins and free fatty acid. J. Boil. Hem. 1982;264:4349–4355
  6. Peterson J, Bihain BE, Bengtsson-Olivecrona G, Deckelbaum RJ, Carpentier YA, Olivecrona T. Fatty acid control of lipoprotein lipase, a link between energy metabolism and lipid transport. Proc. Natl. Acad. Sci. U.S.A. 1990;87:909–913
  7. Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, et al. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin. Chem. Acta. 1993;216:113–123
  8. Tornvall P, Olivecrona G, Carpe F, Andres H, Olivecrona T. Lipoprotein lipase mass and activity in plasma and there increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler. Thromb. Vasc. Biol. 1995;15:1086–1093
  9. Miyashita Y, Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, et al. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res. Clin. Pract. 2002;56:181–187
  10. Shirai K, Itoh I, Sasaki H, Totsuka M, Murano T, Watanabe H, et al. The effect of insulin sensitizer troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res. Clin. Pract. 1999;46:35–41
  11. Hanyu O, Miida T, Obayashi K, Ikarashi T, Soda S, Kaneko S, et al. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis. 2004;174:385–390
  12. Hitsumoto T, Ohsawa H, Uchi T, Noike H, Kanai M, Yoshinuma M, et al. Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis. 2000;153:391–396
  13. Hitsumoto T, Yoshinaga K, Aoyagi K, Sakurai T, Kanai M, Uchi T, et al. Association between preheparin serum lipoprotein lipase mass and acute myocardial infarction in Japanese men. J. Atheroscler. Thromb. 2002;9:163–169
  14. Kannnel WB, McGee DL. Diabetes and cardiovascular disease, the Framingham study. JAMA. 1979;241:2035–2038
  15. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434–444
  16. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–986
  17. Malmberg K. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 1997;314:1512–1515
  18. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837–853
  19. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  20. Shirai K, Nema T, Hiroh Y, Itoh Y, Miyashita Y, Watanabe H. Clinical efficacy of the direct assay method using polymers for serum high density lipoprotein cholesterols. J. Clin. Lab. Anal. 1992;11:82–86
  21. Mead MG, Dangerfield WG. The investigation of midband lipoproteins using polyacrylamide gel electrophoresis. Clin. Chim. Acta. 1974;51:173–182
  22. Watanabe H, Shirai K, Murano T, Hiroh Y, Itoh Y, Miyashita Y. Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis. 1999;145:45–50
  23. Shiba T. Improvement of insulin resistance by a new insulin secretagogue, nateglinide — analysis based on the homeostasis model. Diabetes Res. Clin. Pract. 2003;62:87–94
  24. Annuzzi G, De Natale C, Iovine C, Patti L, Di Marino L, Coppola S, et al. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoprotein in type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 2004;24:2397–2402
  25. Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm. Metab. Res. 1995;27:263–266
  26. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495–506
  27. Austin MA, Breslow JA, Hennekens CH, Buring JE, Willett WC, King MC, et al. Low density lipoprotein subclass pattern and risk of myocardial infarction. J. Am. Med. Assoc. 1988;260:1917–1921

PII: S0168-8227(05)00378-5

doi: 10.1016/j.diabres.2005.09.016

Diabetes Research and Clinical Practice
Volume 72, Issue 1 , Pages 61-67 , April 2006

Article Tools

* Image Usage & Resolution